EUVIMEDEUVIMED entdecken
Crossref

Ligustilide, a novel SIRT1 agonist, alleviates lipopolysaccharide-induced acute lung injury through deacetylation of NICD

Guang Li, Chunxiao Hu, Yan Liu, Huiqing Lin

International Immunopharmacology · 2023-08 · 121 · 110486

DOI: 10.1016/j.intimp.2023.110486 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2023-08. Verfasst von Guang Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Critical Care Medicine, Renmin Hospital, Wuhan University, Wuhan, Hubei Province, China. Hauptthemen laut MEDLINE: Acute Lung Injury, Sepsis, Sirtuin 1. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Lung InjurySepsisSirtuin 1AnimalsMiceInflammationLipopolysaccharidesLungReceptor, Notch14-Butyrolactone

Stichwörter der Autor:innen

Acute lung injuryLigustilideNICDSIRT1

Substanzen

LipopolysaccharidesSirtuin 1Receptor, Notch1ligustilide4-Butyrolactone

Autor:innen und Institutionen

  • Department of Critical Care Medicine, Renmin Hospital, Wuhan University, Wuhan, Hubei Province, China.
  • Department of Transplant Anesthesiology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, China.
  • Department of Thoracic Surgery, Renmin Hospital, Wuhan University, Wuhan, Hubei Province, China.
  • Department of Thoracic Surgery, Renmin Hospital, Wuhan University, Wuhan, Hubei Province, China. Electronic address: huiqing.lin@whu.edu.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Li, G., Hu, C., Liu, Y., & Lin, H. (2023). Ligustilide, a novel SIRT1 agonist, alleviates lipopolysaccharide-induced acute lung injury through deacetylation of NICD. International Immunopharmacology, 121, 110486. https://doi.org/10.1016/j.intimp.2023.110486

Vancouver

Li G, Hu C, Liu Y, Lin H. Ligustilide, a novel SIRT1 agonist, alleviates lipopolysaccharide-induced acute lung injury through deacetylation of NICD. International Immunopharmacology. 2023;121:110486. doi:10.1016/j.intimp.2023.110486

BibTeX
@article{Li2023,
  author = {Li, Guang and Hu, Chunxiao and Liu, Yan and Lin, Huiqing},
  title = {Ligustilide, a novel SIRT1 agonist, alleviates lipopolysaccharide-induced acute lung injury through deacetylation of NICD},
  journal = {International Immunopharmacology},
  year = {2023},
  volume = {121},
  pages = {110486},
  doi = {10.1016/j.intimp.2023.110486}
}
Kostenlos starten →